Govt allows Serum Institute to export 50L Covishield doses to 4 nations

The Union government has allowed the Serum Institute of India to export 50 lakh doses of Covid-19 vaccine Covishield under the UN-backed COVAX global vaccine programme

A health worker administers a dose of Covid-19 vaccine to a visitor at a vaccination centre in Kolkata on October 22, 2021. (PTI Photo/ Swapan Mahapatra)
Press Trust of India New Delhi
1 min read Last Updated : Nov 21 2021 | 8:14 PM IST

The Union government has allowed the Serum Institute of India to export 50 lakh doses of COVID-19 vaccine Covishield under the UN-backed COVAX global vaccine programme to Nepal, Tajikistan and Mozambique, official sources said on Sunday.

In addition to these three countries, the SII will also export Covishield to Bangladesh under COVAX, they said.

The SII will commence Covid vaccine export under the COVAX programme from November 23 and Nepal will receive the first lot of Covishield on November 24.

The government, earlier in October, had permitted the SII to export 10 lakh Covishield doses each to Nepal, Myanmar and Bangladesh under the 'Vaccine Maitri' programme.

In a recent communication to the Union Health Ministry, Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII) is learnt to have informed that the Pune-based firm has manufactured stock of 24,89,15,000 doses of Covishield and that the stock is increasing day by day.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Nov 21 2021 | 8:14 PM IST

Next Story